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The role and frequency of human herpesviruses
(HHV)-6 and -7 in central nervous system (CNS) diseases
of children are unclear. Cerebrospinal fluid samples from
245 pediatric patients (median age 43 days), submitted for
evaluations of possible sepsis or of neurologic symptoms,
were tested for HHV-6 and HHV-7 DNA by polymerase
chain reaction. HHV-6 DNA was found in 3 of 245 samples,
and HHV-7 was found in 0 of 245 samples. The three
patients with HHV-6 DNA were <2 months of age. HHV-6
was likely pathogenic in two patients with meningitis, who
lacked evidence of another microbiologic cause. HHV-6 and
HHV-7 are uncommon causes of CNS infection in children.
HHV-6 may occasionally cause meningitis in young infants. 
H
uman herpesvirus (HHV)-6 and HHV-7 are ubiqui-
tous T-lymphotropic viruses that infect most humans.
Infections with either agent occur primarily during child-
hood. Seroprevalence of HHV-6 reaches >80% in children
>2 years (1–3). Antibody prevalence for HHV-7 reaches
75% in 3- to 6-year-old children and 98% in adults (3–5).
HHV-6 and HHH-7 have been associated with a variety of
clinical manifestations, including fever, rash, and seizures
(6–10). Immunocompromised hosts, particularly trans-
plant recipients, are at increased risk for symptomatic pri-
mary or reactivation disease associated with HHV-6 or
HHV-7 (11–13). 
The role of HHV-6 and 7 in central nervous system
(CNS) disease is an area of ongoing investigation. The
range of CNS manifestations ascribed to these viruses
includes asymptomatic infection, febrile convulsions,
seizure disorders, meningitis, meningoencephalitis, facial
palsy, vestibular neuritis, demyelinating disorders, hemi-
plegia, and, rarely, fatal encephalitis (14–18). Investigators
have been unable to culture HHV-6 or HHV-7 from cere-
brospinal fluid (CSF) (14). However, HHV-6 and HHV-7
DNA have been detected in CSF and other body fluids by
polymerase chain reaction (PCR), which implicates these
viruses in neurologic disorders. HHV-6 DNA was identi-
fied in CSF of 14.8% of children evaluated for fever, sep-
sis, or seizures, with higher prevalence found among chil-
dren with seizures (16). HHV-6 DNA was also detected in
CSF of 70% to 90% of children who had neurologic symp-
toms during their primary HHV-6 infection, with a dispro-
portionate association with recurrent febrile seizures (17).
In a case-control study, HHV-6 DNA was found in CSF of
23% of patients who received an allogeneic bone marrow
transplant who had CNS symptoms; it was found in <1%
of patients with hematologic malignancies without neuro-
logic symptoms (18). Other investigators have found a
much lower prevalence (0%–4%) of HHV-6 DNA in CSF
of AIDS patients with neurologic symptoms and in CSF of
children with febrile seizures (19,20). Similarly, although
HHV-7 DNA has been detected in CSF of as many as
8.8%–14% of children with neurologic symptoms (21,22),
other studies have found a lower prevalence (0%–2%) in
CSF of AIDS patients with neurologic symptoms and in
children with febrile seizures (19,20). 
Because of the conflicting results in the medical litera-
ture, the frequency at which HHV-6 and HHV-7 are asso-
ciated with neurologic disease is unclear. The goal of this
study was to further define the role of HHV-6 and HHV-7
as causes of CNS disease in children. 
Materials and Methods
Study Design 
The study, approved by the University of Colorado
Multiple Institutional Review Board, was conducted with
all CSF clinical samples from pediatric patients submitted
for herpes simplex virus (HSV) PCR to the Clinical
Virology Laboratory at the University of Colorado from
December 1998 through February 2000. When multiple
specimens were submitted for one patient, only the first
one was tested. Specimens positive for other microorgan-
isms were not excluded. Peripheral blood specimens from
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regarding demographics, clinical manifestations, diagnos-
tic studies, management, discharge diagnosis, and outcome
was gathered by retrospective chart review for patients
seen at The Children’s Hospital, Denver. CNS diagnoses
and classification of seizures were based on the assess-
ments of the primary treating physicians.
Definitions
Infectious and postinfectious encephalitis were defined
as the presence of encephalopathy or focal neurologic
abnormalities, an abnormal CSF profile but negative CSF
microbiologic studies, and a history or serologic result
consistent with a current or preceding acute infectious ill-
ness. CSF pleocytosis was defined as >25 leukocytes x
106/L for preterm neonates, >22 leukocytes x 106/L for
term neonates, and >7 leukocytes x 106/L for all other
patients. Infections not involving the CNS were classified
as other infections.
HHV-6 PCR 
HHV-6 PCR was performed (23) with the following
primers and probes (24): 5′ AAG CTT GCA CAA TGC
CAA AAA ACA G (17627–17603), 5′ AAC TGT CTG
ACT GGC AAAAAC TTT T (17405–17429), and 5′ AAC
TGT CTG GCAAAAACTTTT (17516–17492). DNAwas
extracted from 50-µL aliquots of CSF previously stored at
–70°C with Chelex purification matrix (Bio-Rad
Laboratories, Inc, Hercules, CA). PCR was carried out in
50-µL mixtures containing 20 µL of extracted DNA, 1.25
units of PfuI (Stratagene, La Jolla, CA), 200 µmol/Lof each
of four deoxynucleoside triphosphates, and  0.5 µmol/L of
each primer in PfuI buffer (Stratagene). The samples were
amplified in duplicate for 45 cycles. The amplified DNA
was separated according to molecular weight by using 3%
agarose gel electrophoresis and transferred to nylon mem-
branes. The identity of the DNA band (223 bp) was con-
firmed by detection with a digoxigenin-conjugated probe,
antidigoxigenin antibody conjugated to alkaline phos-
phatase (Boehringer Mannheim Biohemicals, Indianopolis,
IN), and chemiluminescent substrate (Tropix, Bedford,
MA). Each patient sample was run in duplicate. Each assay
included two negative controls (water) and two positive
controls (100 genomic copies of HHV-6 DNA/reaction
tube). The tests were considered valid if the controls yield-
ed the expected results, and a specimen was considered
positive if both replicates tested positive. Specimens with
discordant replicates were reanalyzed in an independent run
and considered positive if >50% of replicates gave positive
results. The ability to detect HHV-6 DNAafter at least four
freeze-thaw cycles remained intact.
The analytical sensitivity of HHV-6 PCR was 8–10
copies of genomic DNA per reaction tube, as determined
by serial dilutions of a sample with known DNA copy
number. To rule out the presence of inhibitors in the
extracted DNA, 20 HSV-negative CSF samples were
spiked with the equivalent of 2 HSV DNAcopies per PCR
reaction tube. All samples yielded a positive result for
HSV, whereas the unspiked specimens remained HSV-neg-
ative. The ability to detect HHV-6 strains from different
geographic regions was confirmed by using 14 HHV-
6–containing specimens obtained from diverse laborato-
ries with recognized expertise in diagnosing HHV-6
infections as well as our laboratory. No cross-reactivity
occurred with other DNA viruses, including other her-
pesviruses, parvovirus, adenovirus, and polyomavirus,
thereby establishing the specificity of the HHV-6 PCR. 
HHV-7 PCR
HHV-7 PCR was performed by using the methods
described for HHV-6 with modified sample preparation.
The primers were 5′ TAT CCC AGC TGT TTT CAT ATA
GTAAC and 5′ GCC TTG CGG TAG CAC TAG ATTTTT
TG, and the probe was 5′ AGAATT CTG TAC CCA TGG
GCACATTTG TAC (25; GenBank accession no. L03525).
The PCR product was 186 bp long. The assay included two
negative controls (water) and two positive controls (100
genomic copies of HHV-7 DNA per reaction tube).
The sensitivity of HHV-7 PCR was 8–10 copies of
DNA per reaction tube, as determined by detecting HHV-
7 DNA from samples extracted from infected cells.
Specimens were prepared by boiling aliquots of nonhem-
orrhagic CSF for 55 s. If CSF contained blood, DNA was
extracted with Qiagen DNA extraction kit (Qiagen,
Valencia, CA). Testing with control viral DNA indicated
that boiling did not affect the sensitivity of the PCR. The
presence of inhibitors was ruled out by spiking 20 HSV-
negative CSF samples with the equivalent of two HSV
DNA copies per reaction tube and showing that all spiked
samples became HSV-positive, whereas unspiked samples
remained negative. The ability to detect HHV-7 DNAafter
at least three freeze-thaw cycles remained intact.
Results
Study Population 
CSF samples obtained from 245 patients were tested for
HHV-6 and HHV-7 DNA by PCR. Clinical data were
available for the 218 patients hospitalized at The
Children’s Hospital, Denver (Table 1). The median age
was 43 days; 68% were <2 years of age; 13% were 2–6
years, and 19% >6 years. Fever occurred in 56% of
patients, rash in 11%, and seizures in 25%. CNS disorder
diagnoses at discharge included meningitis in 61 patients
(enteroviral, 21; bacterial, 4; aseptic/indeterminate etiolo-
gy, 36), encephalitis in 21 patients (HSV, 4; acute dissem-
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febrile seizures in 7 patients, and seizure disorder in 29
patients. A non-CNS disease had been diagnosed in the
remaining 100 patients, which included a diagnosis of
other infections in 60. Nineteen patients were immuno-
compromised (leukemia, 6; posttransplant, 3; premature,
3; HIV, 2; others, 5), of whom 1 had a febrile seizure, 1 had
encephalitis, 2 had meningitis, and 5 had other infections.
CSF pleocytosis was found in 90 (43%) of 209 patients for
whom data were available.
HHV-6 Infections of CNS 
PCR identified HHV-6 DNAin CSF of 3 of 245 patients
(Table 2). Patient 1, a 5-day-old full-term male infant of a
diabetic mother, had a generalized seizure on the day he
was born. His seizure was attributed to hypoglycemia
because his concurrent glucose level was 0 mmol/L. On
day 5 of life, a fever of 38.3ºC developed for which he
underwent a complete workup for sepsis. Results of a phys-
ical examination were normal with no signs or symptoms of
neurologic dysfunction. His blood count was remarkable
for a leukocyte count of 8,600 x 106/L (46% neutrophils
and 21% bands) and a platelet count of 40,000 x 106/L. His
CSF showed 40 leukocytes x 106/L (20% neutrophils, 9%
bands, 31% lymphocytes, 33% monocytes, and 6%
macrophages), 4,110 erythrocytes x 106/L, protein 169 g x
10-2/L, and glucose 2.3 mmol/L. CSF HSV PCR, viral cul-
ture, and bacterial cultures of CSF and blood and urine
were negative. Diagnosis at discharge was aseptic meningi-
tis. The patient recovered spontaneously without sequelae.
Patient 2 was a 38-day-old full-term female infant who
had a fever of 39.2ºC and irritability. The physical exami-
nation showed a few vesicular lesions on the tonsillar pil-
lar as well as a diffuse, erythematous, macular blanching
rash. CSF studies found 19 leukocytes x 106/L (34% lym-
phocytes, 12% monocytes, and 55% macrophages), 1 ery-
throcyte x 106/L, protein 48 g x 10-2/L, and glucose 2.3
mmol/L. PCRs of CSF for HSV and enterovirus and bac-
terial cultures of CSF, blood, and urine were negative. She
recovered spontaneously without sequalae. Her discharge
diagnosis was aseptic meningitis. 
Patient 3 was a male infant of 24 weeks’gestation with
respiratory distress syndrome. A blood culture was taken
on day 10 of life because of worsening respiratory distress;
results were positive for Candida. A lumbar puncture was
performed when the blood grew Candida. The patient did
not have any neurologic symptoms or signs. CSF had 1
leukocyte x 106/L, 1,780 erthrocytes x 106/L, protein 105 g
x 10-2/L, and glucose 8.1 mmol/L. CSF studies, including
PCRs for HSV and enterovirus, as well as bacterial, viral,
and fungal cultures, were negative. He subsequently died
of the complications of prematurity and candidal sepsis,
which were unrelated to the CNS. 
All 3 were <2 months of age, and 2 had CSF pleocyto-
sis. Overall, HHV-6 DNA was detected in 2 (2.2%) of 90
specimens from patients with pleocytosis and in 2 (3.3%) of
61 patients with a discharge diagnosis of meningitis. HHV-
6 DNAwas not found in any patients who had encephalitis,
febrile seizures, or a seizure disorder. None of the 19
immunocompromised patients had HHV-6 DNA in CSF.
HHV-7 Infections of CNS
HHV-7 DNAwas not found in any of the 245 CSF sam-
ples tested by PCR. Spiking random samples with HHV-7
DNA generated positive PCR results.
Discussion
HHV-6 DNA was uncommon in CSF of children
(1.2%), and HHV-7 DNA was not detected in any CSF
specimen in this study. HHV-6 DNA was found in a small
percentage of meningitis patients (3.3%), but neither HHV-
6 nor HHV-7 DNA was detected in samples from any
patients with encephalitis, febrile seizures, or seizure disor-
ders. Our limited detection of HHV-6 and HHV-7 contrasts
with results of other studies, such as the report of Caserta et
al. (16), in which HHV-6 DNAwas found in CSF of 14.8%
of children evaluated for fever, sepsis, or seizures, and stud-
ies by Pohl-Koppe et al. (21) and Yoshikawa et al. (22), in
which HHV-7 DNA was found in CSF of 8.8% to 14% of
children with neurologic symptoms. Our findings may have
differed from previous reports for the following reasons: 1)
differences in PCR sensitivity; 2) differences in degree of
intactness of DNA in specimens that were thawed after
being frozen for prolonged periods; 3) geographic varia-
1452 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 8, August 2004
RESEARCH
Table 1. Characteristics of the study population with available 
clinical data
a 
Characteristic   No. patients (%)  
Demographic   
Age: median (range)   43 days (0–5,948 days) 
<2 y   148 (68) 
2–6 y  28 (13) 
>6 y  42 (19) 
Male:female  1.1:1 
Clinical and laborato ry    
Fever  121 (56) 
Rash  24 (11) 
Seizures   53 (25) 
Seizure disorder   29 (55) 
Febrile   7 (13) 
Metabolic  5 (9) 
Infectious/postinfectious   5 (9) 
Intracranial bleed   4 (8) 
Hypoxia  3 (6) 
Meningitis  61 (28) 
Encephalitis  21 (10) 
CSF pleocytosis   90 (43) 
Immunocompromised   19 (9) 
aN = 218; CSF, cerebrospinal fluid.  
 tion; or 4) differences in patient populations and, particular-
ly, differences in age groups. 
Technical laboratory problems were unlikely. Our
assays are as sensitive or more sensitive than those previ-
ously reported that use plasmid-encoded DNA, and we
detected a panel of samples identified by other laborato-
ries, which use different primers or probe sets. However,
these latter experiments were limited in number and could
not completely rule out sensitivity differences related to
the primers and probe sets. The presence of inhibitors was
ruled out by spiking experiments. We tested the effect of
freezing and thawing by subjecting several samples to
three to four freeze-thaw cycles and found good preserva-
tion of both HHV-6 and HHV-7 DNA. Also, the PCR
method used in this study detected cytomegalovirus DNA
in CSF specimens stored at –70°C for up to 6 years (23).
Yoshikawa et al. (22), who reported a 16% incidence of
HHV-6 and HHV-7 in their pediatric patients with neuro-
logic disorders, detected the viral DNAin the CSF cell pel-
let, but not in the liquid phase. Other investigators,
however, who found a high incidence of HHV-6 and HHV-
7 in pediatric patients with neurologic disorders (16,21),
recovered viral DNA from liquid CSF. 
Our results are not likely to be biased by the study pop-
ulation. Although lower seroprevalence rates have been
found in some regions of the world, for example, Morocco
(20% for HHV-6) and northern Japan (44% for HHV-7)
(5,26), no evidence has been found of low seroprevalence
of HHV-6 and HHV-7 infections in specific regions of the
United States. Also, the demographic characteristics of our
study population were similar to those of the 487 children
described by Caserta et al. (16), including a median age
similar to the median age of 1.5 months (range 0.1–36) in
the latter series (16). The populations evaluated by
Yoshikawa et al. (22) and Pohl-Koppe et al. (21) were
somewhat older, with mean ages of 6 and 2.8–6 years,
respectively. However, the number of patients >2 years of
age included in our study population was similar to the
numbers of participants enrolled in these two studies (43
and 68, respectively). Therefore, age differences do not
appear to explain the discrepant findings.
The clinical features of patients 1 and 2 and the absence
of another identified infectious agent suggest that HHV-6
may have been the cause of fever, pleocytosis, and the clin-
ical aseptic meningitis diagnosed in these two infants. Other
studies have not found an association between HHV-6
DNA in CSF and CSF pleocytosis. However, we note that
the CSF of patient 1 was contaminated by blood. Therefore,
the presence and magnitude of pleocytosis are difficult to
state with certainty; moreover, we cannot be certain
whether HHV-6 DNA was truly present in CSF or derived
from contamination with peripheral blood. In patient 3, the
identification of a well-established pathogen and the normal
results of neurologic and CSF examinations suggest that
HHV-6 DNA in the CSF may have represented an asymp-
tomatic infection or contamination with peripheral blood.
The cases of HHV-6 infection of CNS occurred in infants
<2 months of age, and two occurred in the early neonatal
period. Infections in newborns have been previously
described. Although horizontal transmission through saliva
is postulated to be the most common method of transmis-
sion of HHV-6 and HHV-7 (27–29), infection in neonates as
well as detection of HHV-6 DNA in aborted fetuses’ cord
blood and in the female genital tract suggest that transpla-
cental or perinatal transmission is possible (30–33). 
Our study included 29 patients with CNS disorders
caused by a known pathogen other than HHV-6 and HHV-
7 (enterovirus, herpes simplex virus, bacterial pathogen);
none of these patients had HHV-6 or HHV-7 DNA in CSF.
This finding suggests that HHV-6 or HHV-7 DNA is not
frequently detected in CSF in association with other CNS
infections, as might be expected if these viruses estab-
lished latency in CNS and reactivated nonspecifically with
other pathogens. Conversely, this finding supports the idea
that detecting HHV-6 or HHV-7 DNA in CSF of patients
with neurologic disorders is consistent with a pathogenic
role. Our study population included a modest number of
immunocompromised patients of whom a small subset had
neurologic diagnoses. These numbers are insufficient to
ascertain the roles of HHV-6 and HHV-7 in neurologic dis-
ease in immunodeficient patients. 
In conclusion, our data indicate that HHV-6 and HHV-
7 are uncommon causes of CNS infection in children.
HHV-6 may occasionally cause meningitis in young
infants. Further studies are required to define the role of
HHV-6 and HHV-7 in neurologic disorders in immuno-
compromised hosts.
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Table 2. Characteristics of patients with HHV-6 DNA detected in cerebrospinal fluid
a 
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